Company overview
Touchlight is a UK-based CDMO specializing in cell-free enzymatic DNA production using proprietary dbDNA™ technology, offering scalable, high-purity alternatives to plasmid DNA for genetic medicines. They support mRNA, viral and non-viral gene therapies, vaccines, and gene editing from preclinical to GMP stages. Their platform enables rapid manufacturing of grams of DNA with benchtop equipment, addressing limitations of traditional methods.
Touchlight is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include cell-free dna, dbdna, gene therapy, mrna production, gmp dna manufacturing.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://touchlight.com
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- cell-free dna, dbdna, gene therapy, mrna production, gmp dna manufacturing
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What DNA products does Touchlight offer?
- Touchlight manufactures dbDNA™, mbDNA™, and z-dbDNA™—minimal, linear or circular, covalently closed, antibiotic-free DNA constructs produced enzymatically for advanced therapies including AAV production, mRNA, and gene editing.
- What are Touchlight's manufacturing capabilities and scales?
- They provide rapid, scalable DNA production from research use only (RUO) to GMP, with capacity up to 8kg plasmid-equivalent DNA, using disposable benchtop equipment for grams-scale output.
- Does Touchlight support GMP production and regulatory needs?
- Yes, Touchlight offers GMP-certified synthetic DNA as the first globally, supporting clients from preclinical development through clinical supply, licensing, and tech transfer for in-house use.
Related editorial coverage
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives
- Sensorion pivots to SENS-601 after Regeneron’s OTOF hearing loss advance
- $2M Gene Therapy Cures Need a Financing Model
- Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis
- Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know
- FDA Issues June 2026 Guidance: Gene Therapy, Payor Comms, and CMC Flexibilities
Explore lab tools and QA/QC resources for R&D teams.
